Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors

The present invention relates to compounds of the following formula, and pharmaceutically acceptable salts and solvates thereof, wherein: A is C 5-20 heteroaryl or C 5-20 carboaryl, and is optionally substituted; Q 1 is: a covalent bond, a saturated aliphatic C 1-7 alkylene group and is optionally s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LOZA, EINARS, GAILITE, VIJA, ROMERO-MARTIN, MARIA-ROSARIO, HARRIS, C., JOHN, KALVINSH, IVARS, FINN, PAUL, W, RICHIE, JAMES, ANDRIANOV, VICTOR, VORONA, MAXIM, WATKINS, CLARE, J, PISKUNOVA, IRINA, MOORE, KATHRYN, G, DIKOVSKA, KLARA, STARCHENKOV, IGOR, DUFFY, JAMES, E., S
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to compounds of the following formula, and pharmaceutically acceptable salts and solvates thereof, wherein: A is C 5-20 heteroaryl or C 5-20 carboaryl, and is optionally substituted; Q 1 is: a covalent bond, a saturated aliphatic C 1-7 alkylene group and is optionally substituted, or a partially unsaturated aliphatic C 2-7 alkylene group and is optionally substituted; R 1 is hydrogen, C 1-7 alkyl, or C 5-20 aryl; and, Q 2 is -(CH 2 ) n - where n is 4, 5, 6, or 7. The present invention also relates to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.